BioSpace News Archive

Comprehensive Database of 500,000+ Clinical Phenotype Records Supports Ocular Disease Research

Designing Meaningful STEM Lessons shows how teachers in grades 3–8 can take lessons they’re already familiar with and, through small changes, ensure they contain the content students most need to learn.

Researchers are increasingly choosing Quanterix’ ultra-sensitive technology to power advancements in neurology

Proniras Corporation announced that it has been awarded a contract potentially worth $89.5 million from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) to develop tezampanel as a medical countermeasure for the treatment of nerve agent-induced seizures that are not stopped by current medications.

PruittHealth - Moultrie has proven its commitment to an ongoing and concentrated focus on patient-centered quality service delivery.

North Carolina State Veterans Home - Black Mountain has proven its ongoing commitment to a concentrated focus on patient-centered quality service delivery.

PruittHealth, a leader in post-acute care, is partnering for the third year in a row with Second Wind Dreams.

SQI Diagnostics Inc. (“SQI Diagnostics” or the “Company”) (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the three and six months ended March 31, 2018 at 5:00 p.m. ET Thursday, May 10, 2018.

Bolder BioTechnology, Inc. announced today that it has completed a Phase 1 clinical trial of BBT-015, a proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, in healthy human volunteers. BBT-015 is being developed as a treatment for chemotherapy-related neutropenia in cancer patients and for Acute Radiation Syndrome.

Laboratory Designed to Meet Demand for Fully Tested Solutions in Pharma, Biopharma and Food Analysis